12.86
0.22 (1.74%)
| Previous Close | 12.64 |
| Open | 12.78 |
| Volume | 361,137 |
| Avg. Volume (3M) | 743,020 |
| Market Cap | 218,059,504 |
| Price / Earnings (TTM) | 4.54 |
| Price / Sales | 3.00 |
| Price / Book | 4.62 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -7.57 |
| Total Debt/Equity (MRQ) | 333.06% |
| Current Ratio (MRQ) | 4.71 |
| Operating Cash Flow (TTM) | -65.65 M |
| Levered Free Cash Flow (TTM) | -48.59 M |
| Return on Assets (TTM) | -33.79% |
| Return on Equity (TTM) | -267.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Q32 Bio Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.57% |
| % Held by Institutions | 73.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Monimus Capital Management, Lp | 31 Mar 2026 | 134,310 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |